Renewal of revolving credit facility

Summary by AI ^BETAClose X

Eco Animal Health Group plc has renewed its committed revolving credit facility with NatWest, increasing its total banking facilities to £15 million by extending the £10 million revolving credit facility and its existing £5 million overdraft facility to 30 June 2031, on more favourable terms. The company has not utilized the revolving credit facility and has no immediate plans to do so, as it is intended for future business expansion initiatives. Eco Animal Health is currently preparing its audited results for the year ended 31 March 2026, which are anticipated for release around mid-July 2026.

Disclaimer*

Eco Animal Health Group PLC

04 June 2026

4 June 2026

ECO Animal Health Group plc

("ECO" or the "Company")

Renewal of revolving credit facility

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it has renewed its committed revolving credit facility ("RCF") agreement with its bank, National Westminster Bank plc ("NatWest") on more favourable terms than previously existed.

The renewed facility provides for drawings of up to £10 million in flexible amounts and replaces the existing £10 million RCF which was due to expire on 30 June 2026. The Company has also renewed its existing £5m overdraft facility, maintaining total banking facilities of £15 million, with the new RCF and overdraft facility terms expiring on 30 June 2031.

The Company has not previously utilised the RCF and there are no immediate plans to make drawings under the facility; it exists to provide immediate liquidity for business expansion initiatives.

Following the positive trading update announced in March, ECO is currently preparing its audited results for the year ended 31 March 2026 and anticipates releasing these around the middle of July 2026.

-Ends-

Contacts

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)

020 8447 8899

ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

Singer Capital Markets (Nominated Adviser & Joint Broker)

Philip Davies

Jennifer Boorer

Jalini Kalaravy

Samed Ethemi

020 7496 3000

Panmure Liberum (Joint Broker)

Emma Earl

Will Goode

Mark Rogers

Rupert Dearden

020 3100 2000

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin^® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END